Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity

Helle Bach Søndergaard; Eva Rosa Petersen; Melinda Magyari; Finn Sellebjerg; Annette Bang Oturai

doi:10.1016/j.msard.2017.01.015

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity

Helle Bach Søndergaard, Eva Rosa Petersen, Melinda Magyari, Finn Sellebjerg, Annette Bang Oturai

Institut for Klinisk Medicin

10 Citationer (Scopus)

Abstract

Weighted genetic risk score (wGRS) was analysed for association with disease activity in more than 500 MS patients before and during interferon-beta treatment. The wGRS was higher in MS patients than in healthy controls when analysing eight HLA - and 109 non-HLA MS risk gene variants. No significant associations were observed between number of relapses prior to or during treatment with interferon-beta, both with and without HLA risk alleles included in the wGRS. In conclusion, among Danes the wGRS was higher in MS patients than controls but was not associated with the overall disease activity or response to treatment with interferon-beta.

Originalsprog	Engelsk
Tidsskrift	Multiple Sclerosis and Related Disorders
Vol/bind	13
Sider (fra-til)	25-27
ISSN	2211-0348
DOI	https://doi.org/10.1016/j.msard.2017.01.015
Status	Udgivet - 1 apr. 2017

Adgang til dokumentet

10.1016/j.msard.2017.01.015

Citationsformater

@article{4ec445171653443fbc819ac67b09b58d,

title = "Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity",

abstract = "Weighted genetic risk score (wGRS) was analysed for association with disease activity in more than 500 MS patients before and during interferon-beta treatment. The wGRS was higher in MS patients than in healthy controls when analysing eight HLA - and 109 non-HLA MS risk gene variants. No significant associations were observed between number of relapses prior to or during treatment with interferon-beta, both with and without HLA risk alleles included in the wGRS. In conclusion, among Danes the wGRS was higher in MS patients than controls but was not associated with the overall disease activity or response to treatment with interferon-beta.",

keywords = "Adult, Alleles, Female, Genetic Predisposition to Disease, HLA Antigens/genetics, Humans, Interferon-beta/therapeutic use, Male, Multiple Sclerosis/drug therapy, Polymorphism, Single Nucleotide, Risk Factors",

author = "S{\o}ndergaard, {Helle Bach} and Petersen, {Eva Rosa} and Melinda Magyari and Finn Sellebjerg and Oturai, {Annette Bang}",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.msard.2017.01.015",

language = "English",

volume = "13",

pages = "25--27",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity

AU - Søndergaard, Helle Bach

AU - Petersen, Eva Rosa

AU - Magyari, Melinda

AU - Sellebjerg, Finn

AU - Oturai, Annette Bang

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Weighted genetic risk score (wGRS) was analysed for association with disease activity in more than 500 MS patients before and during interferon-beta treatment. The wGRS was higher in MS patients than in healthy controls when analysing eight HLA - and 109 non-HLA MS risk gene variants. No significant associations were observed between number of relapses prior to or during treatment with interferon-beta, both with and without HLA risk alleles included in the wGRS. In conclusion, among Danes the wGRS was higher in MS patients than controls but was not associated with the overall disease activity or response to treatment with interferon-beta.

AB - Weighted genetic risk score (wGRS) was analysed for association with disease activity in more than 500 MS patients before and during interferon-beta treatment. The wGRS was higher in MS patients than in healthy controls when analysing eight HLA - and 109 non-HLA MS risk gene variants. No significant associations were observed between number of relapses prior to or during treatment with interferon-beta, both with and without HLA risk alleles included in the wGRS. In conclusion, among Danes the wGRS was higher in MS patients than controls but was not associated with the overall disease activity or response to treatment with interferon-beta.

KW - Adult

KW - Alleles

KW - Female

KW - Genetic Predisposition to Disease

KW - HLA Antigens/genetics

KW - Humans

KW - Interferon-beta/therapeutic use

KW - Male

KW - Multiple Sclerosis/drug therapy

KW - Polymorphism, Single Nucleotide

KW - Risk Factors

U2 - 10.1016/j.msard.2017.01.015

DO - 10.1016/j.msard.2017.01.015

M3 - Journal article

C2 - 28427696

SN - 2211-0348

VL - 13

SP - 25

EP - 27

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

ER -

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater